Nasal Epinephrine Moves Toward Pharmacist-Supervised Access in New NAPRA Proposal

Community pharmacies have a new access proposal to watch. In a notice published September 28, 2026, NAPRA reported an interim recommendation to place epinephrine nasal spray for emergency treatment of anaphylactic reactions in Schedule II. The recommendation followed the advisory committee’s September 20 meeting. It is not a final scheduling announcement. [1]

What the proposal would mean

Under the national model, Schedule II medicines do not require a prescription, but access still involves a pharmacist’s professional assessment. They are kept outside the public self-selection area. The practical distinction is important: non-prescription does not mean ordinary retail shelf access. [2]

NAPRA is accepting objections until 4 p.m. Eastern time on October 28, 2026. Its notice directs questions and comments to the NDSAC Secretariat at ndsac@napra.ca. The notice does not establish a launch date, reimbursement policy or instructions for an individual product. [1]

National recommendation, local conditions

Drug-schedule implementation is not identical across Canada. Most jurisdictions adopt NAPRA scheduling by reference; British Columbia uses its own approval structure, with corresponding interim treatment of nationally scheduled drugs, and Quebec maintains separate schedules. Teams should confirm the applicable local rules before changing supply procedures. [3]

Pharmasist perspective: This is a workflow-planning story, not a reason to change a patient’s existing emergency treatment plan. Hospital teams may wish to monitor it for discharge counselling, while community teams should distinguish a proposed access category from a product-specific clinical decision.

Practice guidance for pharmacists

• Flag the proposal as interim in staff briefings and patient-facing explanations. [1]
• Calendar the October 28 objection deadline if your team intends to provide feedback. [1]
• Review how pharmacist assessment and non-self-selection storage would fit your workflow if Schedule II status is finalized locally. [2,3]
• Verify your provincial or territorial regulator’s current requirements before changing access or merchandising arrangements. [3]

The next development to watch is NAPRA’s final recommendation and its implications in each jurisdiction. For now, preparation should not be presented as implementation.

Cover illustration: a generic nasal spray concept, not a photograph of a particular epinephrine product.